Literature DB >> 16243476

Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002).

Carmen Betriu1, Iciar Rodríguez-Avial, María Gómez, Esther Culebras, Juan J Picazo.   

Abstract

The evolution of susceptibility to the newer fluoroquinolones, moxifloxacin and trovafloxacin, of Bacteroides fragilis group organisms isolated in our hospital from 1997 to 2002 was studied. A total of 927 strains were included in the study. Trovafloxacin was more active than moxifloxacin against the various species of the group. During the study period, an increase in resistance to both quinolones was observed. Rates of resistance to moxifloxacin at a breakpoint of 8 microg/mL remained stable at around 6% during the period 1997-1998 and increased to 11.4% in 2000 and to 16.5% in 2001-2002 (P<0.005). Resistance to trovafloxacin rose significantly from 0.6% in 1998 to 6.8% in 1999 (P<0.05) and did not change appreciably over the last 3 years studied. This study confirms the increasing resistance of B. fragilis group organisms to trovafloxacin and moxifloxacin and emphasizes the need to perform periodic antimicrobial susceptibility tests to guide the selection of appropriate antimicrobial therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16243476     DOI: 10.1016/j.diagmicrobio.2005.06.012

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  7 in total

1.  Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.

Authors:  Carmen Betriu; Esther Culebras; María Gómez; Fátima López; Iciar Rodríguez-Avial; Juan J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

2.  Mobile genetic elements in the genus Bacteroides, and their mechanism(s) of dissemination.

Authors:  Mai Nguyen; Gayatri Vedantam
Journal:  Mob Genet Elements       Date:  2011-09-01

3.  National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; Y Golan; E J C Goldstein; S M Finegold; L J Harrell; D W Hecht; S G Jenkins; C Pierson; R Venezia; V Yu; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

Review 4.  Bacteroides: the good, the bad, and the nitty-gritty.

Authors:  Hannah M Wexler
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

5.  Antimicrobial susceptibility of clinical isolates of Bacteroides fragilis group organisms recovered from 2009 to 2012 in a Korean hospital.

Authors:  Jisook Yim; Yangsoon Lee; Myungsook Kim; Young Hee Seo; Wan Hee Kim; Dongeun Yong; Seok Hoon Jeong; Kyungwon Lee; Yunsop Chong
Journal:  Ann Lab Med       Date:  2014-12-08       Impact factor: 3.464

6.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

7.  Effects of treatment with enrofloxacin or tulathromycin on fecal microbiota composition and genetic function of dairy calves.

Authors:  Carla Foditsch; Richard V V Pereira; Julie D Siler; Craig Altier; Lorin D Warnick
Journal:  PLoS One       Date:  2019-12-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.